Lineage

Investors Urged to Join Class Action Against Lineage, Inc. After Substantial Losses Post-IPO

by

NEW YORK — A class action lawsuit has emerged against Lineage, Inc., a public company listed on NASDAQ under the ticker symbol LINE, in the United States District Court for the Eastern District of Michigan. The legal action is on behalf of individuals and entities who purchased shares during the company’s initial public offerings (IPOs). The deadline for investors wishing to be appointed as lead plaintiffs in the case is September 30, 2025. Bragar Eagel & Squire, P.C., a law firm specializing in shareholder rights, announced the filing of the suit, inviting those affected to … Read more

Investors Rally as Schall Law Firm Files Class Action Against Lineage, Inc. Over Alleged Securities Violations

by

LOS ANGELES — The Schall Law Firm, a national litigation firm specializing in shareholder rights, has announced the initiation of a class action lawsuit against Lineage, Inc. for alleged violations of federal securities laws. The lawsuit affects investors who purchased Lineage securities that were offered during its initial public offering (IPO) in July 2024. Shareholders who experienced financial losses due to their investment in Lineage are encouraged to make contact with the firm before the deadline of September 30, 2025. The Schall Law Firm is inviting individuals to join the case and recover their losses … Read more

LINE Investors Unite: Join Schall Law Firm in Pursuing Lineage, Inc. Securities Fraud Claims

by

Investors in LINE have the opportunity to participate in a securities fraud lawsuit against Lineage, Inc., led by the Schall Law Firm. This legal action follows allegations that the company may have misrepresented critical information regarding its business practices and financial health, which could have significant implications for shareholders. Lineage, Inc., a biotechnology firm primarily focused on developing innovative therapies, has recently come under scrutiny. The company’s stock has been affected by disclosures that suggest potential discrepancies in their reported data. Investors believe these omissions could have had a material impact on their investment decisions … Read more